HCW Biologics Inc.
14.5M
$1.82M
-23.05
$-0.77
No price alerts set. Add an alert to get notified!
-23.05
-102.22
$-0.77
443.47%
-1,169.70%
-1,148.50%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ACXP
Acurx Pharmaceuticals, Inc.
|
$5.04 | 4.82% | -0.95 | $7.96M | 0.00 |
|
ADIL
Adial Pharmaceuticals, Inc.
|
$1.90 | 2.70% | -0.26 | $1.82M | 0.00 |
|
APRE
Aprea Therapeutics, Inc.
|
$0.77 | 1.53% | -0.47 | $4.84M | 0.00 |
|
APVO
Aptevo Therapeutics Inc.
|
$4.50 | -3.85% | -0.04 | $4.21M | 0.23 |
|
BCDA
BioCardia, Inc.
|
$1.34 | 5.51% | -0.99 | $7.77M | 0.24 |
|
BCLI
Brainstorm Cell Therapeutics Inc.
|
$0.87 | -3.33% | -0.88 | $9.60M | -0.04 |
|
CELZ
Creative Medical Technology Holdings, Inc.
|
$1.86 | -2.11% | -0.81 | $4.80M | 0.00 |
|
INAB
IN8bio, Inc.
|
$1.90 | -7.77% | -0.43 | $8.81M | 0.10 |
|
NRSN
NeuroSense Therapeutics Ltd.
|
$0.82 | 1.07% | -2.41 | $20.22M | 0.00 |
|
RNAZ
TransCode Therapeutics, Inc.
|
$9.40 | 0.53% | -0.29 | $8.62M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$17.80
$0.47
$0.00
0.00%
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
